Manufacturing Oncolytic Viruses: Where Complexity Demands Experience

Key Takeaways

• Oncolytic viruses use many established viral manufacturing technologies, but their dose, concentration, potency, and administration demand product-specific chemistry, manufacturing, and controls strategies.

• High final concentrations create interconnected challenges involving aggregation, impurity accumulation, product loss, advanced analytical strategy, and cost-of-goods evaluation.

• Manufacturing process must preserve replication competence, while potency methods must demonstrate biological activity relevant to the product’s mechanism of action.

• Clinical dose, commercial demand, manufacturing scale, biosafety requirements, raw materials, and supply strategy should shape CMC decisions from the earliest stages.

• Experience is most valuable when it helps teams determine which risks can be reduced through prior knowledge and where product-specific development remains essential.

Interest in oncolytic virus therapies is increasing as advances in diagnostics, viral engineering, and gene-delivery technologies enable more sophisticated approaches to attacking tumors and activating antitumor immune responses. Newer products may combine direct tumor cell lysis with immune stimulation or the delivery of genes and therapeutic proteins intended to enhance anticancer activity.

From a manufacturing perspective, oncolytic viruses share important foundations with viral vaccines and viral vectors. They may rely on related viral backbones, cell substrates, culture systems, upstream technologies, purification operations, analytical principles, and aseptic-processing capabilities. Experience developed through vaccine and vector programs can therefore provide a valuable starting point.

The greatest manufacturing challenge is not that oncolytic viruses require an entirely new set of technologies. It is that decisions concerning dose, concentration, purification, formulation, potency, administration, and commercial supply become unusually interdependent. The intended clinical use changes the target product profile, which can lead to a very different chemistry, manufacturing, and controls (CMC) strategy even when the underlying viral system and production technologies are familiar.

Manufacturing viral vaccines, viral vectors, and oncolytic viruses begins from much the same technical foundation, extending from cell expansion and controlled viral replication through recovery, purification, formulation, and filling. These commonalities can support platform-based development. Prior experience with a viral backbone, cell line, bioreactor format, purification technology, or analytical method may reduce exploratory work at the beginning of a program and help teams anticipate familiar scale-up risks.

The value of that knowledge depends on how closely it matches the new product. Even related viral systems may require different concentrations, impurity profiles, filling volumes, analytical specifications, and process conditions when used for different indications. A platform may transfer substantially in one area while requiring extensive customization elsewhere.

Upstream cell line–technology combinations may provide a particularly useful starting point. Downstream performance is often more product specific because the virus’s surface properties, stability, impurity burden, and required concentration influence filtration, chromatography, formulation, and overall downstream processing recovery. The important question is how the product’s clinical requirements alter the way familiar technologies must be combined and controlled.

One of the most consequential mistakes in oncolytic virus development is treating clinical presentation and commercial demand as downstream considerations rather than manufacturing inputs. The dose required for therapeutic activity, the volume that can be administered, the route and frequency of administration, and the expected patient population should all influence the process from its earliest stages.

A product intended for intratumoral or another volume-constrained route may need to deliver a high number of infectious viral particles in a relatively small volume, driving the final concentration well beyond the levels used during research or early preclinical studies. Commercial demand presents a separate but connected consideration. Many oncolytic viruses are being developed for specialized cancer indications rather than very large patient populations. Their annual volume requirements may remain modest, yet their manufacturing processes can still be technically demanding and expensive.

The most appropriate platform is therefore the one capable of reliably providing the required number of doses at the necessary concentration, quality, and cost. Maximum scale is not necessarily the objective.

A higher clinical dose may require a higher final concentration, which can increase aggregation and product loss. Lower recovery may reduce the number of doses produced per batch and raise cost of goods, influencing campaign size, facility strategy, and commercial feasibility. These cascading effects illustrate why individual decisions cannot be optimized independently.

Many of the challenges that emerge later in oncolytic virus development can be traced back to the concentration required for the final clinical product. Preclinical studies may use relatively dilute material because it is easier to produce and administer in animal models. Those studies may establish biological proof of concept without demonstrating that the eventual human product can be manufactured at the required concentration.

For some programs, downstream processing may need to increase viral concentration by 100- to 200-fold, reducing several hundred liters of harvest to approximately one liter of final drug substance. A manufacturing line must handle that broad range of process volumes while minimizing unrecoverable material. Dead volumes in vessels, tubing, filters, and transfer steps become consequential because even a small volume may contain a meaningful proportion of the batch.

Concentration can also expose the virus to shear, temperature changes, interfaces, extended processing times, and other stresses that increase aggregation or reduce biological activity. Conditions that appear acceptable at laboratory scale may become limiting when a larger process takes longer and involves more transfers and equipment.

Impurities are concentrated alongside the virus. Host-cell DNA, host-cell proteins, and other process- and product-related impurities that appear acceptable at lower concentrations may exceed the intended specifications after substantial volume reduction. Purification must therefore achieve sufficient impurity clearance while preserving acceptable viral recovery.

Each improvement can introduce a competing effect. More intensive purification may reduce impurities but increase product loss. Higher concentration may make clinical administration more practical while increasing aggregation. Additional processing may improve purity but expose the virus to longer hold times and greater stress. A robust strategy must account for those interactions across the process rather than optimize each operation in isolation.

Oncolytic viruses are large, heterogeneous biological structures comprising multiple surface proteins and other components. At high concentration, interactions may occur among viral particles, among different surface proteins, and between the virus and residual host-cell or process-related impurities. These interactions can increase aggregation and other forms of instability, requiring a formulation strategy tailored to the individual virus. A condition that performs well for one viral product cannot be assumed to support another, even when the products use related backbones or production systems.

The clinically preferred concentration may also exceed the level that can be manufactured robustly. Development teams must balance the dose required for therapeutic effect against the volume that can be administered, the concentration the virus can tolerate, achievable impurity clearance, acceptable aggregation, manufacturing recovery, and cost of goods.

Increasing concentration may improve administration while reducing stability and recovery. Reducing the dose may simplify manufacturing but compromise the intended therapeutic strategy. Multiple administrations may provide another clinical option, but they introduce different product, logistical, and patient considerations.

The target product profile must therefore emerge through collaboration among clinical, process-development, formulation, analytical, manufacturing, and regulatory teams. Defining the dose without understanding manufacturing constraints can create an impractical product target, while designing solely around the easiest process may yield a presentation that does not meet the clinical need. Clinical requirements and manufacturing reality should be reconciled early enough to shape development rather than corrected after the process has already been established.

Physical recovery alone is insufficient for a product whose therapeutic effect depends on biological activity. Oncolytic viruses are commonly replication competent, and their ability to infect target cells, replicate, and contribute to tumor cell lysis or other intended effects must be preserved from harvest through final administration.

Unlike vaccine processes designed around an inactivated viral product, an oncolytic virus process must maintain functional viral activity through purification, concentration, formulation, filling, freezing, thawing, and storage. Scale-up can introduce longer processing times, altered mixing and transfer conditions, temperature exposure, and additional interfaces that affect infectivity, replication competence, or potency even when the nominal operating parameters appear comparable.

Analytical development must therefore evolve alongside the process so that teams can determine whether manufacturing changes affect the functions that make the product therapeutic. Potency is especially product specific. Infectivity may represent one important component, but it may not fully reflect the intended mechanism of action. Depending on the product, the potency strategy may also need to assess replication, tumor cell lysis, transgene expression, immune activation, or another functional outcome.

A generic viral assay cannot necessarily establish that an oncolytic virus retains the required biological activity. When no suitable method exists, developing a robust potency assay from the beginning may require more than a year. Potency strategy should therefore be established early enough to support process development, clinical progression, comparability, and eventual release testing.

The broader analytical package may include complementary methods for identity, viral concentration, infectivity, replication competence, potency, purity, safety, and process- and product-related impurities. Platform analytical methods can provide a starting point, but functional assays must remain aligned with the individual product and mechanism of action.

The overall quality framework for viral products is established, but many critical decisions for oncolytic viruses require product-specific scientific justification. Specifications and acceptance criteria may depend on the viral backbone, mechanism of action, route of administration, required dose and concentration, impurity profile, replication competence, patient population, and severity of the disease.

Quality and safety expectations remain rigorous, while the justification for individual specifications and acceptable ranges must reflect the product and its overall risk–benefit context. Impurity specifications established for a prophylactic vaccine cannot simply be assumed to apply to an oncolytic virus. The scientific rationale must account for the product, route of administration, patient population, and clinical use. Product-based risk assessments and timely regulatory discussions help align the manufacturing process, analytical strategy, specifications, and intended therapeutic application.

Replication-competent products also require suitable biosafety and environmental controls. The appropriate containment level depends on the viral system, its pathogenicity, its modifications, and the activities performed. BSL-2 may support many programs, while certain products may require higher containment or additional controls. IDT Biologika operates with BSL-2 capabilities and can support activities up to BSL-3 where required.

Realistic expectations around yield, dose, and cost are essential to a viable oncolytic virus strategy. Developers familiar with vaccine manufacturing may anticipate very large numbers of doses per batch, but those assumptions may not apply when an oncolytic virus requires a much higher concentration and dose. Yields and doses per batch may be lower even though the manufacturing effort remains substantial.

Expectations borrowed from monoclonal antibody production may be equally misleading. Oncolytic viruses are larger, more structurally complex, and potentially more sensitive to purification and concentration conditions. Very high recovery should not be assumed before the individual product has been characterized. These realities can lead to higher cost of goods, which may remain commercially acceptable for a specialized therapy addressing a serious unmet need but should be understood early enough to guide dose, scale, facility, and process decisions.

Raw materials and consumables are part of the same strategy. Related viral processes may use similar technologies but require different single-use assemblies, filters, bags, tubing, sensors, purification materials, and configurations at different scales. Material suitability, GMP availability, supplier reliability, qualification status, and lead times should be assessed during development rather than after the process has been finalized.

Supply planning is therefore part of process design and commercial readiness rather than a separate procurement exercise. Early attention to material requirements and supplier risk can prevent a technically appropriate process from becoming impractical to operate reliably at clinical or commercial scale.

No individual step in oncolytic virus manufacturing is entirely unfamiliar. The challenge lies in how tightly each important decision depends on the ones around it. Concentration affects aggregation, impurities, recovery, formulation, filling, and cost. Purification affects yield and biological activity. Dose and administration influence the target concentration. Potency strategy affects analytical development and release planning. Commercial demand influences scale and technology selection. A decision made in one area can alter the viability of the complete product.

Experience allows teams to recognize those relationships before they become late-stage problems. Prior work with vaccines, viral vectors, and other viral products can inform cell-substrate selection, upstream processing, purification, containment, analytical development, filling, and regulatory strategy. Its value lies in knowing which lessons remain relevant and where the oncolytic product requires new investigation.

Integrated drug substance, drug product, and analytical capabilities can further reduce complexity at the interfaces. Concentration affects formulation; formulation affects stability and filling; freezing and thawing may affect aggregation and potency. When these activities are connected, teams can coordinate hold times, transfer conditions, analytical methods, manufacturing schedules, and investigations with a more complete view of the process.

IDT Biologika combines long-standing viral vaccine and viral vector experience with direct experience supporting commercial oncolytic-virus manufacturing, fixed-bed bioreactor expertise for adherent-cell viral production and suspension-based processes, appropriate biosafety infrastructure, and integrated development, drug substance, drug product, analytical, inspection, release, and packaging capabilities.

Manufacturing experience does not remove the complexity of an oncolytic-virus program. It helps teams determine which risks can be reduced through prior knowledge and which uncertainties require product-specific development. That judgment provides a stronger foundation for converting promising biology into a reliable clinical and commercial product.